SS Innovations International Inc. (NASDAQ: SSII) is charting a course to broaden access to robotic surgery by emphasizing affordability and accessibility, according to a recent interview with founder, chairman and CEO Dr. Sudhir Srivastava. The company's strategy centers on its SSi Mantra surgical robotic platform, designed to reduce costs while supporting multiple specialties, including cardiac surgery. With over 200 robotic systems installed and more than 11,700 procedures completed, including over 170 telesurgeries, SS Innovations is demonstrating the viability of its approach.
Dr. Srivastava discussed the company's objectives in a Medsider interview, highlighting that the goal is not merely to compete with existing platforms but to expand access to hospitals and patients previously unable to adopt robotic surgery due to high equipment costs and operating expenses. Artificial intelligence, automation, and new robotic platforms remain central to the company's long-term product roadmap.
Telesurgery and teleproctoring are emerging as key differentiators, allowing expert surgeons to support complex procedures remotely. This capability addresses the shortage of skilled surgeons in many regions and can accelerate the adoption of robotic surgery in underserved areas. The company's experience with over 170 telesurgeries underscores its leadership in this area.
SS Innovations is actively pursuing regulatory approvals from the U.S. Food and Drug Administration (FDA) and European authorities, while expanding into additional international markets. The SSi Mantra system's design focuses on reducing the cost of robotic surgery, making it more accessible to a broader range of healthcare facilities.
For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results. SS Innovations' focus on cost reduction, training, and remote capabilities positions it to capture market share in the growing surgical robotics sector. The company's track record of over 11,700 procedures provides evidence of clinical acceptance.
More information about SS Innovations is available in the company's newsroom. The company is part of the Dynamic Brand Portfolio @IBN, which delivers access to a vast network of wire solutions, article syndication to 5,000+ outlets, enhanced press release distribution, and social media reach to millions of followers. For further details, visit MissionIR.com.
